

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ADICON Holdings Limited
艾迪康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9860)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR
AND
CHANGE IN THE COMPOSITION OF BOARD COMMITTEE

The board (the “**Board**”) of directors (the “**Director(s)**”) of ADICON Holdings Limited (the “**Company**”) announces that:

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

With effect from August 22, 2025, Mr. ZHU Jonathan (“**Mr. ZHU**”) has been appointed as a non-executive Director and is responsible for providing professional opinion and judgment to the Board. The biographical details of Mr. ZHU are as follows:

Mr. ZHU, aged 57, has extensive experience in the industrial and medical diagnostic industries. Early in his career, from 1992 to 1996, Mr. ZHU was with the US Air Force (USAF). From June 1996 to September 1998, he was the China general manager at Environmental Elements Corporation. He then served as a senior lobbyist at EOP Group, Inc. in Washington, D.C. from June 2000 to June 2005, before becoming a corporate director at HORIBA Group (TSE: 6856), a role he held from June 2005 to January 2010. From September 2014 to October 2022, he led the APAC healthcare and life sciences practice as regional managing partner at Heidrick & Struggles. Since November 2022, Mr. ZHU has been the APAC managing partner of the life sciences practices at Korn Ferry (Sg) Pte Ltd.

Mr. ZHU currently serves as a senior advisor to AdvaMed. His previous advisory appointments include senior advisor to The Carlyle Group (NASDAQ: CG) from 2019 to July 2025, and advisor to the chairman of Shenzhen Hepalink Pharmaceutical Co., Ltd. (深圳市海普瑞藥業集團股份有限公司) (SZSE: 002399, HKEX: 9989) from 2020 to 2024, and member of the Asia advisory board of Coloplast (NASDAQ: COLO-B) from 2013 to 2021.

Mr. ZHU obtained a bachelor's degree in engineering from University of Maryland in the United States in May 1992, an MBA from University of Baltimore in the United States in May 2000 and a master's degree in laws from China University of Political Science and Law in China in 2012.

A letter of appointment has been entered into between Mr. ZHU and the Company for a term of three years commencing from his appointment. Mr. ZHU's appointment as a non-executive Director shall be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Company's articles of association. Mr. ZHU is entitled to a director's fee of RMB732,000 per annum, which is determined by the Board upon recommendation from the remuneration committee of the Board with reference to his qualification, level of duties and responsibilities undertaken in the Company and the prevailing market conditions.

Mr. ZHU has obtained the legal advice referred to in Rule 3.09D of the Listing Rules.

To the best knowledge of the Directors, save as disclosed above, as at the date of this announcement, (i) Mr. ZHU does not have any relationship with any other Directors, senior management, substantial Shareholders or controlling Shareholders of the Company; (ii) Mr. ZHU does not hold any other position within the Company or other members of the Group; (iii) Mr. ZHU does not hold any directorship in any listed public companies which are listed in Hong Kong or overseas in the past three years and other major appointments and professional qualifications; (iv) there is no other information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules, nor are there any other matters that need to be brought to the attention of the Shareholders; and (v) Mr. ZHU does not have any interest in or is deemed to be interested in any shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

CHANGE IN THE COMPOSITION OF BOARD COMMITTEE

With effect from August 22, 2025, Mr. ZHU has been further appointed as a member of the strategy committee of the Board.

By Order of the Board
ADICON Holdings Limited
Ms. YANG Ling
Chairwoman

Hong Kong, August 22, 2025

As at the date of this announcement, the Board comprises Mr. GAO Song as executive Director; Ms. YANG Ling, Mr. LIN Jixun, Ms. FENG Janine Junyuan, Mr. ZHOU Mintao and Mr. ZHU Jonathan as non-executive Directors; and Mr. MI Brian Zihou, Mr. YEH Richard and Mr. ZHANG Wei as independent non-executive Directors.